CD55 regulates the complement system on the cell surface. It recognizes C4b and C3b fragments that are created during classical complement pathway and alternative complement pathway activation and indirectly blocks the formation of the membrane attack complex.
| Inventor | Institute |
|---|---|
| Margaret Goodall | University of Birmingham |
| Cat. #: | 153228 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Immunology |
| Application: | IHC |
| Target: | CD97 Ligand |
| Reactivity: | Human |
| Clone: | BU84 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Complement decay-accelerating factor 55; Dcay accelerating factor for complement; DAF |
|---|---|
| Product description: | CD55 regulates the complement system on the cell surface. It recognizes C4b and C3b fragments that are created during classical complement pathway and alternative complement pathway activation and indirectly blocks the formation of the membrane attack complex. CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours. |
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Immunogen: | Pre-B cells |
| Target background: | CD55 regulates the complement system on the cell surface. It recognizes C4b and C3b fragments that are created during classical complement pathway and alternative complement pathway activation and indirectly blocks the formation of the membrane attack complex. CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Leucocyte Typing VI, (1998): edited by T. Kishimoto, Garland Publishing, New York. Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663. Origin and properties of soluble CD21 (CR2) in human blood. Buescher et al. 1991. Public Health Rep. 106(3):333-8. PMID: 1905057. Problems in estimating the number of women in need of subsidized prenatal care. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.